TaiMed Biologics Inc (中裕新藥), an HIV/AIDS drug developer, yesterday denied that it is eyeing profits from an anticipated spike in the spread of the disease following the Council of Grand Justices’ ruling that paved the way for the legalization of same-sex marriage.
The rumors are malicious and have damaged the company’s reputation, it said in a filing with the Taiwan Stock Exchange.
The company said that research on its HIV/AIDS drug TMB-355 began more than a decade ago and it placed a lower priority on commercializing the drug in the Taiwan market since listing on the Taipei Exchange in November 2015.
“Due to stringent controls imposed on drug prices under the National Health Insurance scheme, we have ruled out expectations of significant profit in the domestic market,” the company said, adding that its focus is on overseas markets.
The company said that the US market for AIDS/HIV treatments is about 100 times larger than the local market and it has submitted a new drug application to US health authorities.
None of its major stakeholders have strong political leanings, TaiMed said, adding that it has not been in contact with political figures, interest groups or institutions.
Same-sex marriage is a social issue rather than an economic or business matter, it said.
While employees are free to voice their opinions on the matter, TaiMed does not have a stance, it said.
The company urged the government to develop legislation to mitigate social discord.
Meanwhile, TaiMed president and chief executive officer James Chang (張念原) said at a shareholders’ meeting on Friday last week that the company hopes TMB-355 would contribute to sales before the end of the year.
The company has invested more than US$30 million to prepare for TMB-355’s launch in the US, and it has hired 25 salespeople and secured four distribution partnerships there, Chang said.
A protein-drug manufacturing plant in Hsinchu is to break ground this month and is expected to help reduce production costs by the second half of next year, he said.
Investors have been battered by a recent bubble in the local biotechnology sector, he said, adding that the firm’s shares have been undervalued.
TaiMed shares yesterday gained 5.85 percent to close at NT$190, outpacing the Taipei Exchange’s 0.04 percent rise.
BUSINESS UPDATE: The iPhone assembler said operations outlook is expected to show quarter-on-quarter and year-on-year growth for the second quarter Hon Hai Precision Industry Co (鴻海精密) yesterday reported strong growth in sales last month, potentially raising expectations for iPhone sales while artificial intelligence (AI)-related business booms. The company, which assembles the majority of Apple Inc’s smartphones, reported a 19.03 percent rise in monthly sales to NT$510.9 billion (US$15.78 billion), from NT$429.22 billion in the same period last year. On a monthly basis, sales rose 14.16 percent, it said. The company in a statement said that last month’s revenue was a record-breaking April performance. Hon Hai, known also as Foxconn Technology Group (富士康科技集團), assembles most iPhones, but the company is diversifying its business to
Apple Inc has been developing a homegrown chip to run artificial intelligence (AI) tools in data centers, although it is unclear if the semiconductor would ever be deployed, the Wall Street Journal reported on Monday. The effort would build on Apple’s previous efforts to make in-house chips, which run in its iPhones, Macs and other devices, according to the Journal, which cited unidentified people familiar with the matter. The server project is code-named ACDC (Apple Chips in Data Center) within the company, aiming to utilize Apple’s expertise in chip design for the company’s server infrastructure, the newspaper said. While this initiative has been
GlobalWafers Co (環球晶圓), the world’s No. 3 silicon wafer supplier, yesterday said that revenue would rise moderately in the second half of this year, driven primarily by robust demand for advanced wafers used in high-bandwidth memory (HBM) chips, a key component of artificial intelligence (AI) technology. “The first quarter is the lowest point of this cycle. The second half will be better than the first for the whole semiconductor industry and for GlobalWafers,” chairwoman Doris Hsu (徐秀蘭) said during an online investors’ conference. “HBM would definitely be the key growth driver in the second half,” Hsu said. “That is our big hope
The consumer price index (CPI) last month eased to 1.95 percent, below the central bank’s 2 percent target, as food and entertainment cost increases decelerated, helped by stable egg prices, the Directorate-General of Budget, Accounting and Statistics (DGBAS) said yesterday. The slowdown bucked predictions by policymakers and academics that inflationary pressures would build up following double-digit electricity rate hikes on April 1. “The latest CPI data came after the cost of eating out and rent grew moderately amid mixed international raw material prices,” DGBAS official Tsao Chih-hung (曹志弘) told a news conference in Taipei. The central bank in March raised interest rates by